GSA Capital Partners’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

GSA Capital Partners’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-30,247	Closed	-$249K	–	2046
2022 Q3	$249K	Sell	30,247 -3,163	-9%	-$24.3K	0.03%	1057
2022 Q2	$219K	Buy	+33,410	New	+$162K	0.03%	1031
2021 Q4	–	Sell	-35,232	Closed	-$218K	–	1977
2021 Q3	$218K	Buy	+35,232	New	+$211K	0.02%	1197
2020 Q3	–	Sell	-33,447	Closed	-$172K	–	1480
2020 Q2	$172K	Sell	33,447 -57,525	-63%	-$363K	0.1%	385
2020 Q1	$329K	Buy	90,972 +9,673	+12%	+$48K	0.08%	427
2019 Q4	$508K	Buy	81,299 +68,764	+549%	+$506K	0.06%	636
2019 Q3	$106K	Sell	12,535 -8,512	-40%	-$63.3K	0.01%	1273
2019 Q2	$142K	Sell	21,047 -47,796	-69%	-$409K	0.02%	1298
2019 Q1	$565K	Buy	+68,843	New	+$711K	0.06%	620
2017 Q4	–	Sell	-1,470	Closed	-$54K	–	1936
2017 Q3	$54K	Buy	+1,470	New	+$45.5K	﹤0.01%	1547

Other funds holding AVEO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

GSA Capital Partners's AVEO Position: Q4 2022 in Review

GSA Capital Partners sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2022, closing a stake of 30,247 shares — an estimated $249K sold.

GSA Capital Partners first reported a position in AVEO in Q3 2017 and held it in 10 quarters. The position peaked at $565K in Q1 2019. 110 funds tracked by Wall St. Rank hold AVEO as of Q4 2022.

GSA Capital Partners reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
GSA Capital Partners sold 30,247 AVEO Pharmaceuticals, Inc. shares in Q4 2022, an estimated $249K.
GSA Capital Partners first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2017 and held it in 10 quarters.
GSA Capital Partners's AVEO Pharmaceuticals, Inc. position peaked at $565K in Q1 2019.
110 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.